Quintiles News

Please select a press release from the list below, or filter and sort to find a specific press release.

Latest Press Release

Quintiles Announces Pricing of $800 Million Senior Notes Offering

RESEARCH TRIANGLE PARK, NC – May 6, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) (the “Company” or “Quintiles”) announced today that Quintiles Transnational Corp. (“Quintiles Transnational”), its wholly owned subsidiary, has priced $800 million principal amount of 4.875% senior unsecured notes due 2023 (the “Senior Notes”) offered in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities... Learn More
Published Date: All 2015 2014 2013 2012 2011 2010
Press Release May 06, 2015
RESEARCH TRIANGLE PARK, NC – May 6, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) (the “Company” or “Quintiles”) announced today that Quintiles Transnational Corp. (“Quintiles Transnational”), its wholly owned subsidiary, has priced $800 million principal amount of 4.875% senior unsecured notes due 2023 (the “Senior Notes”) offered in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Company intends to use the net proceeds of the offering, together with proceeds from its previously announced proposed senior secured credit facility, which is expected to increase to a total of $1.95 billion, including $1.45 billion of term loans, to refinance its existing credit facility, as well as for...
Read More
Press Release May 04, 2015
RESEARCH TRIANGLE PARK, NC – May 4, 2015 – Quintiles today announced the expansion of its bioanalytical laboratory services with the establishment of a GLP-compliant bioanalytical liquid chromatography-mass spectrometry (LC-MS) laboratory. The laboratory, which is located in Oss, the Netherlands, will have extensive bioanalytical testing capabilities and will provide a European facility for Quintiles customers to conduct pharmacokinetics studies.  The Oss laboratory facility combines a cohort of employees with extensive industry experience, automated processes, and a state-of-the-art facility equipped to increase high-quality throughput. The new laboratory is led by Dr. Benno Ingelse, an industry expert with more than 15 years of (bio)analytical experience.  In addition, the Oss...
Read More
Press Release May 04, 2015
Research Triangle Park, NC - Quintiles CFO Kevin Gordon will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015 in Las Vegas at the Encore Wynn. The Quintiles presentation will begin at 12:00 p.m. PDT. Investors may access a live audio webcast of the presentation on the Quintiles’ Investor Relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 33,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-75 best-selling drugs on the market....
Read More
Press Release May 01, 2015
RESEARCH TRIANGLE PARK, N.C. – May 1, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) (the “Company” or “Quintiles”) announced today a proposed offering by its wholly owned subsidiary, Quintiles Transnational Corp. (“Quintiles Transnational”), of $800 million principal amount of senior unsecured notes due 2023 (the “Senior Notes”), subject to market and other conditions. The Senior Notes will be offered in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Company intends to use the net proceeds of the offering, together with proceeds from its previously announced proposed new senior secured credit facility, to refinance its existing credit facilities, as well as for general corporate...
Read More
Press Release Apr 30, 2015
RESEARCH TRIANGLE PARK, N.C. – April 30, 2015 – Quintiles, the world’s largest biopharmaceutical services company, has been named to the InformationWeek Elite 100, a ranking of the top business technology innovators in the U.S. In compiling the InformationWeek Elite 100, the publication tracks the technology-based investments, strategies and results of some of the best-known organizations in the country.  Unique among corporate rankings, the Elite 100 spotlights the power of business technology innovation.  Quintiles was previously named to the InformationWeek 500 for five consecutive years. Accelerating the Clinical Trial Process:  Quintiles Infosario® Site Targeting Quintiles was named to the 2015 InformationWeek Elite 100 for its innovative Quintiles Infosario Site Targeting...
Read More
Press Release Apr 29, 2015
RESEARCH TRIANGLE PARK, N.C., April 29, 2015 – Quintiles Transnational Holdings Inc. (the “Company” or “Quintiles”) (NYSE: Q) announced today that it is proposing, subject to market and other conditions, to enter into $1.75 billion of new senior secured credit facilities consisting of a $500 million revolving credit facility and $1.25 billion of term loans, and to issue $800 million aggregate principal amount of unsecured debt.  The Company intends to use the net proceeds of the offering of the unsecured debt, together with the new term loans, to refinance its existing credit facilities, as well as for general corporate purposes, including corporate transactions and equity repurchases.  The refinancing transactions would be entered by Quintiles Transnational Corp., the Company’s...
Read More
Press Release Apr 29, 2015
Research Triangle Park, NC, April 29, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) today reported its financial results for the quarter ended March 31, 2015. $1.35 billion of net new business representing a 1.31 book-to-bill ratio 8.4% constant currency service revenue growth compared to the first quarter of 2014 $0.72 diluted adjusted earnings per share representing 5.9% growth compared to the first quarter of 2014 and first quarter GAAP reported diluted earnings per share of $0.68 Updating full year 2015 service revenue constant currency growth guidance to 7.0% - 8.0% compared to full year 2014 and reaffirming diluted adjusted EPS guidance of $3.02 - $3.13 per share, representing diluted adjusted EPS growth of 12% to 16% compared...
Read More
Press Release Apr 16, 2015
RESEARCH TRIANGLE PARK, N.C. – April 16, 2015 – Quintiles today announced a strategic alliance with Hospital Italiano of Buenos Aires as part of the company’s Prime Site program. Hospital Italiano is Quintiles’ first Prime Site in Latin America, complementing the company’s robust network of investigative sites across the globe. A Prime Site is a large clinical institution selected by Quintiles to work together and enhance the institution’s infrastructure for conducting clinical trials in order to accelerate the development of new and more effective medicines. Quintiles and a Prime Site work together to create a more efficient clinical trial process by recruiting, enrolling and retaining more patients through the course of a clinical trial. The new agreement with Hospital Italiano is...
Read More
Press Release Apr 09, 2015
RESEARCH TRIANGLE PARK, N.C. – April 9, 2015 – For the third time in the last four years, Quintiles has been named Best Clinical Research Organization (CRO) at the Vaccine Industry Excellence (ViE) Awards. Presented at the World Vaccine Congress in Washington, D.C., the awards recognize the efforts and achievements of companies and individuals in the vaccine industry during the previous year. “We are honored to once again receive this prestigious award reflecting the insight of many from across the biopharmaceutical industry,” said Phil Breitfeld, vice president and head of the Therapeutic Centers of Excellence at Quintiles. “It is clear to us all that the healthcare industry has a tremendous opportunity to conquer the global burden of disease. We’re proud to be working alongside our...
Read More
Press Release Mar 31, 2015
Combines the complementary strengths and scale of leading biopharmaceutical services and diagnostic information services providers New entity creates superior value proposition through the depth and scale of its capabilities, services and expertise Business to help biopharmaceutical customers bring new drug therapies to market and support precision medicine Joint venture would have generated approximately $575 million in revenues in 2014 Quintiles will own 60% and Quest Diagnostics will own 40% of the joint venture Investor teleconference scheduled for March 31 at 8:30 a.m. ET RESEARCH TRIANGLE PARK, N.C. and MADISON, N.J. – March 31, 2015 – Quintiles and Quest Diagnostics today announced a definitive agreement to form a global clinical trials laboratory services...
Read More
Press Release Mar 25, 2015
RESEARCH TRIANGLE PARK, N.C. – March 25, 2015 – Quintiles, the world’s largest biopharmaceutical services company, has been named to Forbes magazine’s first-ever “America’s Best Employers” list as rated by more than 20,000 independent survey responses. Quintiles is ranked as the 30th best employer in the United States and comes in third in the “Drugs and Biotechnology” category. In all, 500 companies are included in the 2015 Forbes list. “Being named one of the top employers in the U.S. is a great honor for Quintiles and says a lot about our values, our people and company mission,” said Chief Human Resources Officer Garrett Walker. “Our organization is committed to building and sustaining a work environment that enables our talent to be high performing, successful in achieving their...
Read More
Press Release Mar 24, 2015
SINGAPORE – March 25, 2015 – Quintiles Head of Asia Markets Anand Tharmaratnam, M.D., last night was honored as “Best Life Science Asian Male Executive of the Year” at the BioPharma Asia Industry Awards.  Dr. Tharmaratnam was selected in a vote of biopharmaceutical industry professionals from five distinguished executives shortlisted for the award. “On behalf of the hundreds of voters who made their voices heard in the competition, we are pleased to present this award to Dr. Tharmaratnam,” said Sharon Roessen, Managing Director of Terrapinn Pte Ltd, organizer of BioPharma Asia Convention 2015.  “His visionary leadership and Quintiles’ stellar work were frequent themes in voter comments. We would like to thank Anand for his contributions to advancing Asia’s biopharma industry.” Over the...
Read More
Press Release Feb 27, 2015
RESEARCH TRIANGLE PARK, NC – February 27, 2015 – Quintiles CEO Tom Pike will present at the 2015 Barclays Global Healthcare Conference on Tuesday, March 10, 2015 in Miami at the Loews Miami Hotel. The Quintiles presentation will begin at 11:15 a.m. (EST). Investors may access a live audio webcast of the presentation on the Quintiles Investor Relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100...
Read More
Press Release Feb 25, 2015
RESEARCH TRIANGLE PARK, N.C. – February 25, 2015 – Quintiles announced today that it has been named to the 2015 CSO50 by IDG's CSO magazine in recognition of the company’s risk mitigation strategy managing Windows XP security challenges. CSO commended the Quintiles team for its innovative defense-in-depth model which minimized security risks for business-critical applications dependent on Windows XP, delivering secure and segmented platforms while protecting critical company assets. “This was an innovative solution to a problem that presents significant security concerns for many organizations around the world,” said Quintiles Chief Information Security Officer Patricia Collins Weedon. “Quintiles has launched many innovative customer solutions that require our team to think beyond current...
Read More
Press Release Feb 24, 2015
RESEARCH TRIANGLE PARK, NC – February 24, 2015 – Quintiles today announced the appointment of Elgar Peerschke to serve as president, Advisory Services. In this role, Peerschke is responsible for leading Quintiles’ Advisory Services organization and the continued development and delivery of its related services. Bringing more than 25 years of experience to Quintiles, Elgar joins Quintiles from Bain & Company, a global business consulting firm, where he was a senior partner in its Global Healthcare Practice Group and a leading client service partner. Prior to Bain, Elgar spent more than a decade at McKinsey and Company in various leadership roles. “Throughout his career, Elgar has focused on the healthcare industry, providing cutting-edge insight and guidance in boardrooms of...
Read More
Press Release Feb 19, 2015
RESEARCH TRIANGLE PARK, N.C. – February 19, 2015 – Quintiles, the world’s largest biopharmaceutical services company, has been named to FORTUNE magazine’s “World’s Most Admired Companies” list for 2015. Quintiles is ranked third overall in FORTUNE’s Healthcare: Pharmacy and Other Services category with the top ranking for the reputation attribute of “global competitiveness” and second within the segment for its “people management.” FORTUNE's World's Most Admired Companies list is the definitive report card on corporate reputations. Since 1997, Fortune has identified, selected and ranked the World’s Most Admired Companies, uncovering the business practices that make these companies highly regarded among their peers. “I would like to congratulate Quintiles’ employees around the world for...
Read More
Press Release Feb 10, 2015
RESEARCH TRIANGLE PARK, N.C. – February 10, 2015 – Quintiles, the world’s largest biopharmaceutical services company, is working with the National Football League (NFL) to track player injuries and understand trends in injury occurrence. Quintiles and the NFL have been working together since 2011, when the Quintiles epidemiology group was tasked with designing a new application that would modernize the league’s existing Injury Surveillance System (ISS). The NFL recently signed a five-year agreement with Quintiles to continue and expand upon its Injury Surveillance and Analytics (ISA) service as it is now known. Quintiles records injury occurrence during pre-season training, and continues throughout the regular season and playoffs. For the 2014-15 season, Quintiles began conducting injury...
Read More
Press Release Feb 06, 2015
RESEARCH TRIANGLE PARK, NC – February 6, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) announced today that Dr. John Leonard, MD, has been appointed to its Board of Directors, effective immediately.  Dr. Leonard will also serve as a member of the Audit and Governance Committees of the Board.   Dr. Leonard serves as chief medical officer for Cambridge, MA-based Intellia Therapeutics, a private biotech company, in a position he has held since 2014.  Prior to Intellia, Dr. Leonard served as the chief scientific officer and senior vice president of research and development at AbbVie Inc., a global pharmaceutical company, since its spin-out from Abbott Laboratories in January 2013 until retiring from those positions at the end of 2013. Prior to the...
Read More
Press Release Feb 06, 2015
RESEARCH TRIANGLE PARK, NC – February 6, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) announced today that its Board and principal shareholders have reached agreement on a governance plan to transition the Company’s Board of Directors and its committees to comply with NYSE criteria as a non-controlled company. Quintiles’ Stockholders Agreement has been amended, calling for the Quintiles Board to be set at nine members, comprised of a majority of independent directors by November 2015. In the interim, the Board size will be increased to 13 to make room for two additional independent directors, the first of whom is Dr. John Leonard, an experienced pharmaceutical development executive, who was appointed to the Board on February 5, 2015. Commencing in...
Read More
Press Release Jan 22, 2015
SEOUL – January 23, 2015 – Quintiles today announced the launch of a handbook to guide physicians in the conduct of investigator initiated clinical trials. Top clinical researchers from academia and industry across Asia-Pacific joined Quintiles’ experts in contributing to and editing the handbook, which Quintiles sponsored as part of its ongoing efforts to enhance clinical research globally and create a healthier world. Availability of the handbook, “Investigator Initiated Trials Made Easy,” was announced at a press conference held at Seoul National University Hospital in South Korea. “Investigator initiated, patient-focused clinical trials play a vital role in improving and expanding patient care in the real world,” said Dr. Stephanie Tan, MBBS, Quintiles Site and Patient Network, Asia,...
Read More